Study S000039

FITWISE: Feasibility Study of Tirzepatide for Weight Loss Intervention in Early-Stage Hormone Receptor Positive/HER2 Negative Breast Cancer

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT06518837
Acronym: FITWISE
Study type: INTERVENTIONAL
Phase: PHASE2
Masking: NONE
Status: RECRUITING
Enrollment: 40
Start: 2024-10-30
Primary completion: 2027-09-30
Lead sponsor: Rutgers, The State University of New Jersey
Conditions: Hormone Receptor-Positive Breast Cancer; HER2-Negative Breast Cancer
Interventions: DRUG:Tirzepatide
Results posted: FALSE
Individual participant data sharing: NO

Registered primary outcomes

Weight Loss Reduction with Tirzepatide during Adjuvant Treatment for HR+/Her2- Breast Cancer (Measured by Body Weight Reduction) [Through study completion, total of two years.]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.